Your browser doesn't support javascript.
Molecular Epidemiology of SARS-CoV-2 in Tunisia (North Africa) through Several Successive Waves of COVID-19.
Chouikha, Anissa; Fares, Wasfi; Laamari, Asma; Haddad-Boubaker, Sondes; Belaiba, Zeineb; Ghedira, Kais; Kammoun Rebai, Wafa; Ayouni, Kaouther; Khedhiri, Marwa; Ben Halima, Samar; Krichen, Henda; Touzi, Henda; Ben Dhifallah, Imen; Guerfali, Fatma Z; Atri, Chiraz; Azouz, Saifeddine; Khamessi, Oussema; Ardhaoui, Monia; Safer, Mouna; Ben Alaya, Nissaf; Guizani, Ikram; Kefi, Rym; Gdoura, Mariem; Triki, Henda.
  • Chouikha A; Reasearch Laboratory "Virus, Vectors and Hosts: One Health Approach and Technological Innovation for a Better Health", LR20IPT02, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Fares W; Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Laamari A; Clinical Investigation Center (CIC), Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Haddad-Boubaker S; Reasearch Laboratory "Virus, Vectors and Hosts: One Health Approach and Technological Innovation for a Better Health", LR20IPT02, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Belaiba Z; Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Ghedira K; Clinical Investigation Center (CIC), Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Kammoun Rebai W; Reasearch Laboratory "Virus, Vectors and Hosts: One Health Approach and Technological Innovation for a Better Health", LR20IPT02, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Ayouni K; Reasearch Laboratory "Virus, Vectors and Hosts: One Health Approach and Technological Innovation for a Better Health", LR20IPT02, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Khedhiri M; Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Ben Halima S; Clinical Investigation Center (CIC), Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Krichen H; Reasearch Laboratory "Virus, Vectors and Hosts: One Health Approach and Technological Innovation for a Better Health", LR20IPT02, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Touzi H; Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Ben Dhifallah I; Clinical Investigation Center (CIC), Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Guerfali FZ; Laboratory of Bioinformatics, Biomathematics and Biostatistics (BIMS), Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Atri C; Laboratory of Biomedical Genomics and Oncogenetics (LR16IPT05), Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1068, Tunisia.
  • Azouz S; Reasearch Laboratory "Virus, Vectors and Hosts: One Health Approach and Technological Innovation for a Better Health", LR20IPT02, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Khamessi O; Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Ardhaoui M; Clinical Investigation Center (CIC), Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Safer M; Reasearch Laboratory "Virus, Vectors and Hosts: One Health Approach and Technological Innovation for a Better Health", LR20IPT02, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Ben Alaya N; Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Guizani I; Clinical Investigation Center (CIC), Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Kefi R; Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Gdoura M; Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
  • Triki H; Reasearch Laboratory "Virus, Vectors and Hosts: One Health Approach and Technological Innovation for a Better Health", LR20IPT02, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis 1002, Tunisia.
Viruses ; 14(3)2022 03 17.
Article in English | MEDLINE | ID: covidwho-1753688
ABSTRACT
Documenting the circulation dynamics of SARS-CoV-2 variants in different regions of the world is crucial for monitoring virus transmission worldwide and contributing to global efforts towards combating the pandemic. Tunisia has experienced several waves of COVID-19 with a significant number of infections and deaths. The present study provides genetic information on the different lineages of SARS-CoV-2 that circulated in Tunisia over 17 months. Lineages were assigned for 1359 samples using whole-genome sequencing, partial S gene sequencing and variant-specific real-time RT-PCR tests. Forty-eight different lineages of SARS-CoV-2 were identified, including variants of concern (VOCs), variants of interest (VOIs) and variants under monitoring (VUMs), particularly Alpha, Beta, Delta, A.27, Zeta and Eta. The first wave, limited to imported and import-related cases, was characterized by a small number of positive samples and lineages. During the second wave, a large number of lineages were detected; the third wave was marked by the predominance of the Alpha VOC, and the fourth wave was characterized by the predominance of the Delta VOC. This study adds new genomic data to the global context of COVID-19, particularly from the North African region, and highlights the importance of the timely molecular characterization of circulating strains.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study Topics: Variants Limits: Humans Country/Region as subject: Africa Language: English Year: 2022 Document Type: Article Affiliation country: V14030624

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study Topics: Variants Limits: Humans Country/Region as subject: Africa Language: English Year: 2022 Document Type: Article Affiliation country: V14030624